USPTO Trademark for Stem Cell Medical Devices and Drug Delivery

ChangeBridge: Trademarks - Medical Devices (Class 010)

Detected March 25th, 2026

Summary

The USPTO has received an intent-to-use trademark application for goods and services related to stem cell medical devices, drug delivery systems, and stem cell therapies. The application covers a range of products and services, including implantable drug delivery devices, stem cell processing and application devices, and stem cell bank services.

View original document View source feed page

What changed

This document details an intent-to-use trademark application filed with the USPTO (Application No. 99109369) on March 28, 2025. The application seeks to register trademarks for a broad scope of goods and services primarily related to stem cells and drug delivery for medical purposes. This includes stem cells for medical use, drug delivery systems (implantable devices, catheters, micro-robots), regenerative medicinal products, cell processing and application devices, stem cell bank services, and related research and development services.

While this is a trademark filing and not a regulatory rule, it indicates a company's intent to market specific medical products and services. Compliance officers in the pharmaceutical and medical device sectors should note this filing as it pertains to potential future market activities and product claims related to stem cell therapies, cancer treatment, and autoimmune/inflammatory diseases. No immediate compliance actions are required based on this filing, but it may signal future product launches or marketing campaigns that will need to adhere to relevant FDA regulations.

Source document (simplified)

← USPTO Trademark Applications

BREAKING THROUGH DEFENSES, DELIVERING HOPE

Intent to Use TM99109369 Kind: intenttouse Mar 24, 2026

Abstract

Stem cells for medical purposes; Drug delivery systems, namely, implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the treatment of rare diseases tumors, cancer, auto-immune, and inflammatory diseases; stem cell delivery agent in the form of micro-beads for use in stem cell delivery for patients; regenerative medicinal products, namely, cell, cellular component, and stem cell processing and application medical devices for medical application being cell growth media for growing cells for use medical use; Drug delivery systems, namely, implantable subcutaneous drug delivery device in the nature of drug delivery ports; drug delivery systems primarily comprised of drug delivery catheters and medical micro-robots for delivering stem cells into a targeted area in humans; stem cell delivery apparatus for medical use, namely, implantable stem cell delivery ports, medical mic-robots for stem cell delivery; medical biohybrid, synthetic and hybrid micro-robots for use in stem cell delivery for patients; apparatus for the regeneration of stem cells for medical purposes; regenerative medicinal products, namely, cell, cellular component, and stem cell processing and application medical devices for medical application being cell regeneration apparatus; regenerative medicinal products, namely, cell, cellular component, and stem cell extraction medical devices for medical application being needles for medical purposes; medical apparatuses for implementing treatment methods using stem cells; Stem cell therapy services; Providing information in the field of stem-cell therapies and stem-cell therapies related to tumors, cancer, auto-immune and inflammatory diseases; stem call bank services; medical services relating to the removal, treatment and processing of stem cells; Research and development in the field of stem-cell therapies; Research and development in the field of stem-cell therapies for treatment of tumors, cancer, auto-immune, and inflammatory diseases; research and development in the field of stem-cell therapies, namely, synthetic induced mesenchymal stem-cell therapies (iMSC); Stem cell research services; Stem cells for research or scientific purposes; stems cells for medical research